AUTHORS'SYNOPSIS Left ventricular function and isovolumic indices of contractility were
examined in the awake, chronically instrumented dog to assess their ability to detect …

Background In patients with atrial fibrillation undergoing percutaneous coronary intervention
(PCI) with placement of stents, standard anticoagulation with a vitamin K antagonist plus …

Background Dronedarone is a new antiarrhythmic drug that is being developed for the
treatment of patients with atrial fibrillation. Methods We conducted a multicenter trial to …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

Aims Cardiovascular disease is the most common cause of mortality and morbidity in the
world, but the pharmaceutical industry's willingness to invest in this field has declined …

Estrogen and insulin-like-growth factor 1 (IGF-1) are potent mitogenic stimuli that share
important properties in the control of cellular proliferation. However, the coupling between …

Aims Although non-vitamin K antagonist oral anticoagulants are recommended for stroke
prevention in patients with non-valvular atrial fibrillation (NVAF) based on clinical trial …

Background Limited data are available on the characteristics, clinical management, and
outcomes of patients with atrial fibrillation at risk of stroke, from a worldwide perspective. The …

Aims X-VeRT is the first prospective randomized trial of a novel oral anticoagulant in patients
with atrial fibrillation undergoing elective cardioversion. Methods and results We assigned …

Cardiac hypertrophy is a common and often lethal complication of arterial hypertension.
Atrial natriuretic peptide (ANP) has been postulated to exert local antihypertrophic effects in …